Literature DB >> 27156619

Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China.

Peng Xu1, Jie Wu2, Chongguang Yang1, Tao Luo3, Xin Shen2, Yangyi Zhang2, Chijioke A Nsofor1, Guofeng Zhu4, Brigitte Gicquel5, Qian Gao6.   

Abstract

Pyrazinamide (PZA) is an important first-line anti-tuberculosis drug, however, there are relatively few available data on PZA resistant (PZA-R) rate in China. From June 2009 to June 2012, we selected 493 isolates from five field settings in China to investigate PZA-R by pncA gene sequencing. The result showed that PZA-R rate was 1.0% (2/196) among pan-susceptible isolates, 3.1% (4/130) among isoniazid (INH) mono-resistant isolates, 14.0% (6/43) among rifampin (RIF) mono-resistant isolates and 43.5% (54/124) among multidrug resistant (MDR) isolates. MDR tuberculosis (TB), RIF mono-resistance, and retreatment were found to be risk factors for PZA-R. Newly diagnosed PZA-R TB patients and clustered isolates with identical pncA mutations indicate that transmission of PZA-R isolates plays an important role in emergence of PZA-R TB. The results suggest that, it is necessary to conduct PZA susceptibility test among MDR isolates and modify the treatment regimens accordingly.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Mycobacterium tuberculosis; Pyrazinamide resistance; Transmission

Mesh：

Substances：

Year:  2016        PMID： 27156619      PMCID： PMC5647815          DOI： 10.1016/j.tube.2016.02.008

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN： 1472-9792            Impact factor:   3.131


  31 in total

1.  Mycobacterium tuberculosis and non-tuberculous mycobacteria isolates from HIV-infected patients in Guangxi, China.

Authors:  R Lan; C Yang; L Lan; J Ou; K Qiao; F Liu; Q Gao
Journal:  Int J Tuberc Lung Dis       Date:  2011-12       Impact factor: 2.373

Review 2.  The role of pyrazinamide in tuberculosis chemotherapy.

Authors:  M A Steele; R M Des Prez
Journal:  Chest       Date:  1988-10       Impact factor: 9.410

3.  Characterization of pncA gene mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Mexico.

Authors:  Betzaida Cuevas-Córdoba; Sheila Oyuki Xochihua-González; Aremy Cuellar; Javier Fuentes-Domínguez; Roberto Zenteno-Cuevas
Journal:  Infect Genet Evol       Date:  2013-01-12       Impact factor: 3.342

4.  Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Japan.

Authors:  H Ando; S Mitarai; Y Kondo; T Suetake; J-I Sekiguchi; S Kato; T Mori; T Kirikae
Journal:  Clin Microbiol Infect       Date:  2009-10-14       Impact factor: 8.067

5.  Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.

Authors:  Eric Nuermberger; Sandeep Tyagi; Rokeya Tasneen; Kathy N Williams; Deepak Almeida; Ian Rosenthal; Jacques H Grosset
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

6.  Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand.

Authors:  Jirarut Jonmalung; Therdsak Prammananan; Manoon Leechawengwongs; Angkana Chaiprasert
Journal:  BMC Microbiol       Date:  2010-08-20       Impact factor: 3.605

7.  Evaluation of methods for testing the susceptibility of clinical Mycobacterium tuberculosis isolates to pyrazinamide.

Authors:  Zhenling Cui; Jie Wang; Junmei Lu; Xiaochen Huang; Ruijuan Zheng; Zhongyi Hu
Journal:  J Clin Microbiol       Date:  2013-02-06       Impact factor: 5.948

8.  Mycobacterium tuberculosis Beijing strains favor transmission but not drug resistance in China.

Authors:  Chongguang Yang; Tao Luo; Guomei Sun; Ke Qiao; Gang Sun; Kathryn DeRiemer; Jian Mei; Qian Gao
Journal:  Clin Infect Dis       Date:  2012-08-03       Impact factor: 9.079

9.  Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.

Authors:  Ian M Rosenthal; Ming Zhang; Kathy N Williams; Charles A Peloquin; Sandeep Tyagi; Andrew A Vernon; William R Bishai; Richard E Chaisson; Jacques H Grosset; Eric L Nuermberger
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

10.  Evolution and transmission of drug-resistant tuberculosis in a Russian population.

Authors:  Nicola Casali; Vladyslav Nikolayevskyy; Yanina Balabanova; Simon R Harris; Olga Ignatyeva; Irina Kontsevaya; Jukka Corander; Josephine Bryant; Julian Parkhill; Sergey Nejentsev; Rolf D Horstmann; Timothy Brown; Francis Drobniewski
Journal:  Nat Genet       Date:  2014-01-26       Impact factor: 38.330
View more
  9 in total

Review 1.  Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective.

Authors:  Emily A Kendall; Ted Cohen; Carole D Mitnick; David W Dowdy
Journal:  Int J Infect Dis       Date:  2016-12-19       Impact factor: 3.623

2.  Transmissible Mycobacterium tuberculosis Strains Share Genetic Markers and Immune Phenotypes.

Authors:  Hanna Nebenzahl-Guimaraes; Arjan van Laarhoven; Maha R Farhat; Valerie A C M Koeken; Jornt J Mandemakers; Aldert Zomer; Sacha A F T van Hijum; Mihai G Netea; Megan Murray; Reinout van Crevel; Dick van Soolingen
Journal:  Am J Respir Crit Care Med       Date:  2017-06-01       Impact factor: 21.405

3.  Pyrazinamide Resistance and Mutation Patterns Among Multidrug-Resistant Mycobacterium tuberculosis from Henan Province.

Authors:  Jie Shi; Ruyue Su; Danwei Zheng; Yankun Zhu; Xiaoguang Ma; Shaohua Wang; Hui Li; Dingyong Sun
Journal:  Infect Drug Resist       Date:  2020-08-20       Impact factor: 4.003

4.  Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan.

Authors:  Muhammad Tahir Khan; Shaukat Iqbal Malik; Sajid Ali; Nayyer Masood; Tariq Nadeem; Anwar Sheed Khan; Muhammad Tanvir Afzal
Journal:  BMC Infect Dis       Date:  2019-02-06       Impact factor: 3.090

5.  Drug-Resistant Characteristics, Genetic Diversity, and Transmission Dynamics of Rifampicin-Resistant Mycobacterium tuberculosis in Hunan, China, Revealed by Whole-Genome Sequencing.

Authors:  Wencong He; Yunhong Tan; Chunfa Liu; Yiting Wang; Ping He; Zexuan Song; Dongxin Liu; Huiwen Zheng; Aijing Ma; Bing Zhao; Xichao Ou; Hui Xia; Shengfen Wang; Yanlin Zhao
Journal:  Microbiol Spectr       Date:  2022-02-16

6.  Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China.

Authors:  Yang Che; Dingyi Bo; Xiang Lin; Tong Chen; Tianfeng He; Yi Lin
Journal:  BMC Infect Dis       Date:  2021-06-25       Impact factor: 3.090

7.  Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.

Authors:  Yu Pang; Damian Zhu; Huiwen Zheng; Jing Shen; Yan Hu; Jie Liu; Yanlin Zhao
Journal:  BMC Infect Dis       Date:  2017-11-06       Impact factor: 3.090

Review 8.  Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains.

Authors:  H M Adnan Hameed; Md Mahmudul Islam; Chiranjibi Chhotaray; Changwei Wang; Yang Liu; Yaoju Tan; Xinjie Li; Shouyong Tan; Vincent Delorme; Wing W Yew; Jianxiong Liu; Tianyu Zhang
Journal:  Front Cell Infect Microbiol       Date:  2018-04-10       Impact factor: 5.293

9.  Detection of Novel Gene Mutations Associated with Pyrazinamide Resistance in Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates in Southern China.

Authors:  Hm Adnan Hameed; Yaoju Tan; Md Mahmudul Islam; Zhili Lu; Chiranjibi Chhotaray; Shuai Wang; Zhiyong Liu; Cuiting Fang; Shouyong Tan; Wing Wai Yew; Nanshan Zhong; Jianxiong Liu; Tianyu Zhang
Journal:  Infect Drug Resist       Date:  2020-01-22       Impact factor: 4.003
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.